Prognostic value of bcl-2 expression in patients with operable carcinoma of the uterine cervix

Journal of Clinical Pathology

Volumn 50, Issue 1, 1997, Pages 33-36

  Tjalma, W ^a,b   Weyler, J ^a   Goovaerts, G ^b   De Pooter, C ^a   Van Marck, E ^c   Van Dam, P ^a,c  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b SINT AUGUSTINUS HOSPITAL   (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Bcl 2; Cervical cancer; Immunohistochemistry; Prognosis

Indexed keywords

PROTEIN BCL 2;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; UTERINE CERVIX CARCINOMA;

EID: 0031019588     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.50.1.33     Document Type: Article

References (32)

1. Kerr JFR, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994;73:2013-23.
2. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
3. Akao Y, Otsuki Y, Kataoka S, Ito Y, Tsujimoto Y. Multiple subcellular localization of bcl-2: detection in nuclear outer membrane, endoplasmic reticulum membrane, and mitochondrial membrane. Cancer Res 1994;54:2468-71.
4. Chen-Levy Z, Cleary ML. Membrane topology of the bcl-2 proto-oncogenic protein demonstrated in vitro. J Biol Chem 1990;265:4929 33.
5. De Jong D, Prins FA, Mason DY, Reed JC, Van Ommen GB, Kluin PM. Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer Res 1904; 54:256 60.
6. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mithochondrial membranes. Cancer Res 1993;53:4701 14.
7. Monaghan P, Robertson D, Amos TAS, Dyer MJS, Mason DY, Greaves MF. Ultrastructural localization of bcl-2 protein. J Histochem Cytochem 1992;40:1819-25.
8. Shepherd JH. Cervical and vulva cancer: changes in FIGO definitions of staging. Br J Obstet Gynaecol 1996;103:405-6.
9. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
10. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
11. Sanders CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe FS, et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993;82:1994 2004.
12. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, et al. Bcl-2 protein in non-small-cell lung carcinoma. N Eng J Med 1993;329:690 4.
13. Baretton GB, Diebold J, Christoforis G, Vogt M, Müller C, Dopfer K, et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Cancer 1996;77:255-64.
14. Hellemans P, van Dam PA, Weyler J, Van Oosterom AT, Buytaert P, Van Marck E. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 1995;72:354-60.
15. Diebold J, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M, et al. Bcl-2 expression and apoptosis in ovarian tumors. Verh Dtsch Ges Pathol 1994;78:641.
16. Levine EL, Davidson SE, Roberts SA, Chadwick CA, Potten CS, West CML. Apoptosis as predictor of response to radiotherapy in cervical carcinoma. Lancet 1994;344:472.
17. bax. J Biol Chem 1995;270:26049 52.
18. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69:119-28.
19. Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP, Green DR. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 1992;257:212-14.
20. Bissonette RP, Echeverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992;359:552-4.
21. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 proto-oncogene. Nature 1992; 359:554-6.
22. Liang XH, Mungal S, Ayscue A, Meissner JD, Wodnicki P, Hockenbery D, et al. Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. J Cell Biochem 1995;57:509-521.
23. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, et al. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph-node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499 504.
24. Miyashita T, Krajewski S, Krajewska M, Wong HG, Lin HK, Liebermann DA, et al. Tumor supressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-805.
25. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM, Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54:2095-7.
26. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus type 16 and 18 E6 proteins with p53. Science 1990;248:76-9.
27. Dyson N, Howley PM, Münger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-7.
28. Fischer TC, Milner AE, Gregory CD, Jackmann AL, Aherne GW, Hartley JA, et al. Bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 1993;53:3321-6.
29. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993;81:3091-6.
30. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in human leukemia cell line. Blood 1993;81:151 7.
31. Gee JMW, Robertson JFR, Ellis OA, Willsher P, McClelland RA, Hoyle HB, et al. Immunocytochemical localisation of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994;59:619-28.
32. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995;55:4471-8.